Cystic Fibrosis Market

The global Cystic Fibrosis Market is valued at USD 10.4 Billion in 2023 and is projected to reach a value of USD 55.4 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 21.6% between 2024 and 2032. The Market is driven by increasing awareness of the disease, advancements in treatment options, rising prevalence of cystic fibrosis, and growing investments in R&D for innovative therapies.

Key Highlights

• In 2023, North America dominated the market with 42.60% market share
• By Drug Class, the Cystic Fibrosis Transmembrane Conductane Regulator (CFTR) segment is dominated the market with 69.20% market share in 2023
• Based on route of administration, the Oral segment is dominated the market with 60.30% market share
• Based on distribution channel, the Retail Pharmacies & Drug Store segment is dominated the market share

Drug Class Overview

The Drug Class Segment is divided into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others. The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) held the dominant share in 2023, accounting for significant market share of 69.20%.

The transmembrane conductance regulator (CFTR) protein is a chloride channel in the body that regulates the movement of chloride and sodium across all cell membranes in the lungs and other organs. CFTR modulators improve cellular function, helps to reduce lung flare-ups and respiratory symptoms by improving body function and enhancing patients' quality of life. For Instance, in july 2023, Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis Targeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor (ER) positive / human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer. Under the terms of the agreement, Pfizer will pay Arvinas $650 million upfront. Separately, Pfizer will make a $350 million equity investment in Arvinas.

Route of Administration Overview

The route of administration segment is divided into oral, Inhalation, Injectable, and Others. The Oral held the dominant share in 2023, accounting for significant market share of 60.30%.

There is a rise in the adoption of oral drugs globally, and the advent of new formulation drugs that can be consumed easily without the risk of invasive procedures to obtain effective treatment.

The growing usage of noninvasive medical interventions such as injections and inhalations will witness the highest CAGR growth owing to the preference for these options by medical practitioners.

Inhaled drugs can be very well administered in high-risk patient groups that include cystic fibrosis patients suffering from respiratory disorders.

Regional Overview

In 2023, the North America captured 42.60% of the revenue share.

North America Cystic Fibrosis market is driven by advanced healthcare infrastructure, presence of major players, and reimbursements, are expected to drives the market growth. The regional leading contribution is primarily due to the rising incidence of cystic fibrosis and the availability of multiple treatment options in the region. The rising disease prevalence, advanced healthcare infrastructure, and high adoption rates of novel therapies drives the market growth.

The US held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by high prevalence of the disease, advanced healthcare infrastructure, and robust research and development activities. Additionally, strong support from government initiatives, patient advocacy groups, and increased funding for cystic fibrosis research further propel market growth.

In Asia Pacific, Cystic Fibrosis market is experiencing notable growth, driven by increasing awareness of the disease, improved diagnostic capabilities, and expanding healthcare infrastructure. Countries such as India, China, and Japan are witnessing growth in research and development activities, along with the introduction of advanced treatments and therapies. However, challenges such as limited access to specialized treatments and a lack of widespread awareness still exist, but the region's potential remains significant as healthcare systems evolve and more patients gain access to innovative cystic fibrosis treatments.

Key Regions and Countries

North America

• The US
• Canada
• Rest of North America

Europe

• Germany
• France
• The UK
• Spain
• Netherlands
• Russia
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• Singapore
• Thailand
• South Korea
• Vietnam
• India
• New Zealand
• Rest of Asia Pacific

Latin America

• Mexico
• Brazil
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• South Africa
• UAE
• Rest of the Middle East & Africa

Key Trends

• Advancement in CFTR Modulator Therapies: The development of highly effective CFTR modulator therapies has revolutionized treatment by targeting the underlying cause of cystic fibrosis, improving patient outcomes
• Rising Awareness and Screening Programs: Rising awareness and screening programs for cystic fibrosis enhance early detection and intervention, leading to improved patient outcomes. Increased education efforts among healthcare professionals and the public promote timely diagnosis and treatment access
• Improved Diagnostic Technologies: Improved diagnostic technologies enable earlier and more accurate identification of cystic fibrosis, facilitating timely treatment and better management of the disease

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing Spending on R&D Research

Growing investment in R&D research within the industry, coupled with other technological advancements in this therapeutic area, will open new avenues of growth for industry participants. Researchers at the NIH has developed a wearable sensor that helps in the diagnosis and monitoring of disease progression. The sensor detects the improper salt balance in the body of patients and transmits the data wirelessly for analysis. A range of oral and inhaled medication is available for the treatment that increases compliance to the treatment owing to the ease and convenience of administering it. Rising innovation in the development of new therapies and drug products to cure the disease is anticipated to expand the cystic fibrosis market over the analysis period.

High Treatment Costs

High treatment costs represent a significant barrier in the cystic fibrosis market, impacting patient access to essential therapies. Innovative treatments, such as CFTR modulators and gene therapies, while effective, often come with exorbitant price tags that can strain healthcare budgets and lead to financial burdens for patients and families. Many health insurance plans may not fully cover these high costs, resulting in out-of-pocket expenses that are unsustainable for some patients. Consequently, this financial barrier can hinder treatment adherence and ultimately affect patient outcomes, as individuals may be forced to forego necessary medications due to their prohibitive costs.

Competitive Landscape

The Cystic Fibrosis market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Mylan N.V., Novartis AG, Gilead Sciences Inc, Pfizer Inc, Bayer AG, Astrazeneca, Vertex Pharmaceuticals Inc, Genentech Inc, Other Companies. competition in the market is intensifying as companies invest in research and development, collaborate with academic institutions, and engage in clinical trials to bring new therapies to market. Additionally, strategic partnerships, mergers, and acquisitions are common as companies seek to enhance their product offerings and expand their market presence.

Company List:

• Vertex Pharmaceuticals Incorporated
• AbbVie Inc.
• Gilead Sciences, Inc.
• Genentech, Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Perrigo Company plc
• Pharmaxis Ltd.
• Celtaxsys, Inc.
• Savara Inc.
• Kamada Ltd.
• Chiesi Farmaceutici S.p.A.
• Galapagos NV
• Proteostasis Therapeutics, Inc.
• Eloxx Pharmaceuticals, Inc.
• Insmed Incorporated
• Arcturus Therapeutics Holdings Inc.
• Translate Bio, Inc.
• Zogenix, Inc.

Recent Market Developments

Viatris Supports the Cystic Fibrosis Community Through Expanded Access to Treatment and Beyond

• In April 2023, At Viatris, they support the nearly 40,000 adults and children in the U.S. living with cystic fibrosis (CF) during Cystic Fibrosis Awareness Month in May and year-round. This support stems from our core mission of empowering people worldwide to live healthier at every stage of life by expanding access to important treatments. While no cure currently exists, treatments and medications can help manage CF symptoms. By leveraging our capabilities and improving access to effective treatments, Viatris helps people get the medications they need, regardless of geography or circumstance

Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie

• In July 2024, Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), announced that it has obtained exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with AbbVie. Under the terms of the agreement, Sionna will assume all development responsibilities for galicaftor (ABBV-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and navocaftor (ABBV-3067), a CFTR potentiator, both of which have completed Phase 2 studies, and a Phase 1 TMD1-directed corrector, ABBV-2851